Subset of Stage I Melanoma Patients ID’d With Very Low Mortality
Younger age at diagnosis, Clark level II linked to low risk for death among patients with stage I lesions, negative clinical nodes.
Younger age at diagnosis, Clark level II linked to low risk for death among patients with stage I lesions, negative clinical nodes.
The optimal sequence of treatment for BRAF-mutant melanoma is nivolumab-ipilimumab followed by dabrafenib-trametinib, a study suggests.
Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition.
Following an initial extensive review, the Agency identified less than 20 cases of SCC and less than 30 cases of various lymphomas in the capsule around the breast implant.
Researchers explored the effects of developing ICI-related colitis on patients treated with ipilimumab as monotherapy and dual therapy for advanced melanoma.
First-line immune checkpoint inhibitors have improved survival in patients with metastatic melanoma but remain underused in this population.
Researchers sought to determine the effect of delays in surgical treatment delays of 1 to 5 months on overall and disease-specific mortality in patients with melanoma.
Adding T-VEC to pembrolizumab does not improve survival in patients with advanced melanoma, a phase 3 study suggests.
Patients with AJCC IIIA and sentinel node metastatic tumor deposits ≥0.3 mm have lower five-year disease-specific survival rates.
Researchers found that racial and socioeconomic factors were linked to melanoma survival in women of childbearing age.